Single- and multiple-dose pharmacokinetics of oral creatine

Adam M. Persky, Markus Müller, Hartmut Derendorf, Maria Grant, Gayle A. Brazeau, Günther Hochhaus

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Supplementation with exogenous creatine (Cr) has shown physiological benefits in humans, but little is known about the pharmacokinetics of Cr in humans. Six healthy males completed an open-label study consisting of a full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 days of Cr administration (71 mg kg-1 qid). After the single oral dose, the clearance (CL/F) was 0.20 ± 0.066 L h-1 kg-1, tmax was 1.9 ± 0.88 hours, and Cmax = 102.1 ± 11.2 mg h L-1. At steady-state, CL/F decreased to 0.12 ± 0.016 L h-1 kg-1, tmax did not change, and Cmax increased to 162.2 ± 30.0 mg L-1. Penetration (AUCMUSCLE/AUCPLASMA) of Cr into the interstitial muscle space, as determined by microdialysis, was 0.47 ± 0.09 and 0.37 ± 0.27 for the single dose and at steady-state, respectively. Plasma and muscle data were simultaneously fitted with a model incorporating a saturable absorption and firstorder elimination process. In conclusion, repeated dosing of Cr caused a reduction in clearance that could result from saturation of the skeletal muscle pool of Cr.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalJournal of Clinical Pharmacology
Volume43
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Creatine
Pharmacokinetics
Muscles
Microdialysis
Skeletal Muscle

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Persky, A. M., Müller, M., Derendorf, H., Grant, M., Brazeau, G. A., & Hochhaus, G. (2003). Single- and multiple-dose pharmacokinetics of oral creatine. Journal of Clinical Pharmacology, 43(1), 29-37. https://doi.org/10.1177/0091270002239703

Single- and multiple-dose pharmacokinetics of oral creatine. / Persky, Adam M.; Müller, Markus; Derendorf, Hartmut; Grant, Maria; Brazeau, Gayle A.; Hochhaus, Günther.

In: Journal of Clinical Pharmacology, Vol. 43, No. 1, 01.01.2003, p. 29-37.

Research output: Contribution to journalArticle

Persky, AM, Müller, M, Derendorf, H, Grant, M, Brazeau, GA & Hochhaus, G 2003, 'Single- and multiple-dose pharmacokinetics of oral creatine', Journal of Clinical Pharmacology, vol. 43, no. 1, pp. 29-37. https://doi.org/10.1177/0091270002239703
Persky AM, Müller M, Derendorf H, Grant M, Brazeau GA, Hochhaus G. Single- and multiple-dose pharmacokinetics of oral creatine. Journal of Clinical Pharmacology. 2003 Jan 1;43(1):29-37. https://doi.org/10.1177/0091270002239703
Persky, Adam M. ; Müller, Markus ; Derendorf, Hartmut ; Grant, Maria ; Brazeau, Gayle A. ; Hochhaus, Günther. / Single- and multiple-dose pharmacokinetics of oral creatine. In: Journal of Clinical Pharmacology. 2003 ; Vol. 43, No. 1. pp. 29-37.
@article{2b2da7d868f24b06ae0d9edf54414a82,
title = "Single- and multiple-dose pharmacokinetics of oral creatine",
abstract = "Supplementation with exogenous creatine (Cr) has shown physiological benefits in humans, but little is known about the pharmacokinetics of Cr in humans. Six healthy males completed an open-label study consisting of a full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 days of Cr administration (71 mg kg-1 qid). After the single oral dose, the clearance (CL/F) was 0.20 ± 0.066 L h-1 kg-1, tmax was 1.9 ± 0.88 hours, and Cmax = 102.1 ± 11.2 mg h L-1. At steady-state, CL/F decreased to 0.12 ± 0.016 L h-1 kg-1, tmax did not change, and Cmax increased to 162.2 ± 30.0 mg L-1. Penetration (AUCMUSCLE/AUCPLASMA) of Cr into the interstitial muscle space, as determined by microdialysis, was 0.47 ± 0.09 and 0.37 ± 0.27 for the single dose and at steady-state, respectively. Plasma and muscle data were simultaneously fitted with a model incorporating a saturable absorption and firstorder elimination process. In conclusion, repeated dosing of Cr caused a reduction in clearance that could result from saturation of the skeletal muscle pool of Cr.",
author = "Persky, {Adam M.} and Markus M{\"u}ller and Hartmut Derendorf and Maria Grant and Brazeau, {Gayle A.} and G{\"u}nther Hochhaus",
year = "2003",
month = "1",
day = "1",
doi = "10.1177/0091270002239703",
language = "English (US)",
volume = "43",
pages = "29--37",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Single- and multiple-dose pharmacokinetics of oral creatine

AU - Persky, Adam M.

AU - Müller, Markus

AU - Derendorf, Hartmut

AU - Grant, Maria

AU - Brazeau, Gayle A.

AU - Hochhaus, Günther

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Supplementation with exogenous creatine (Cr) has shown physiological benefits in humans, but little is known about the pharmacokinetics of Cr in humans. Six healthy males completed an open-label study consisting of a full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 days of Cr administration (71 mg kg-1 qid). After the single oral dose, the clearance (CL/F) was 0.20 ± 0.066 L h-1 kg-1, tmax was 1.9 ± 0.88 hours, and Cmax = 102.1 ± 11.2 mg h L-1. At steady-state, CL/F decreased to 0.12 ± 0.016 L h-1 kg-1, tmax did not change, and Cmax increased to 162.2 ± 30.0 mg L-1. Penetration (AUCMUSCLE/AUCPLASMA) of Cr into the interstitial muscle space, as determined by microdialysis, was 0.47 ± 0.09 and 0.37 ± 0.27 for the single dose and at steady-state, respectively. Plasma and muscle data were simultaneously fitted with a model incorporating a saturable absorption and firstorder elimination process. In conclusion, repeated dosing of Cr caused a reduction in clearance that could result from saturation of the skeletal muscle pool of Cr.

AB - Supplementation with exogenous creatine (Cr) has shown physiological benefits in humans, but little is known about the pharmacokinetics of Cr in humans. Six healthy males completed an open-label study consisting of a full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 days of Cr administration (71 mg kg-1 qid). After the single oral dose, the clearance (CL/F) was 0.20 ± 0.066 L h-1 kg-1, tmax was 1.9 ± 0.88 hours, and Cmax = 102.1 ± 11.2 mg h L-1. At steady-state, CL/F decreased to 0.12 ± 0.016 L h-1 kg-1, tmax did not change, and Cmax increased to 162.2 ± 30.0 mg L-1. Penetration (AUCMUSCLE/AUCPLASMA) of Cr into the interstitial muscle space, as determined by microdialysis, was 0.47 ± 0.09 and 0.37 ± 0.27 for the single dose and at steady-state, respectively. Plasma and muscle data were simultaneously fitted with a model incorporating a saturable absorption and firstorder elimination process. In conclusion, repeated dosing of Cr caused a reduction in clearance that could result from saturation of the skeletal muscle pool of Cr.

UR - http://www.scopus.com/inward/record.url?scp=0037215275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037215275&partnerID=8YFLogxK

U2 - 10.1177/0091270002239703

DO - 10.1177/0091270002239703

M3 - Article

C2 - 12520625

AN - SCOPUS:0037215275

VL - 43

SP - 29

EP - 37

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -